{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:15:16Z","timestamp":1791900916864,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11940-019-0568-z","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T07:08:11Z","timestamp":1556521691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Current Treatment Options in Neurology\u2014SMA Therapeutics"],"prefix":"10.1007","volume":"21","author":[{"given":"Megan A.","family":"Waldrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"issue":"3","key":"568_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jmg.10.3.260","volume":"10","author":"JH Pearn","year":"1973","unstructured":"Pearn JH. The gene frequency of acute Werdnig-Hoffmann disease (SMA type 1). A total population survey in North-East England. J Med Genet. 1973;10(3):260\u20135.","journal-title":"J Med Genet"},{"issue":"1","key":"568_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27\u201332. \n                      https:\/\/doi.org\/10.1038\/ejhg.2011.134\n                      \n                    .","journal-title":"Eur J Hum Genet"},{"key":"568_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2018.02.022","volume":"1693","author":"CE Beattie","year":"2018","unstructured":"Beattie CE, Kolb SJ. Spinal muscular atrophy: selective motor neuron loss and global defect in the assembly of ribonucleoproteins. Brain Res. 2018;1693(Pt A:92\u20137. \n                      https:\/\/doi.org\/10.1016\/j.brainres.2018.02.022\n                      \n                    .","journal-title":"Brain Res"},{"issue":"6","key":"568_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"Stephen J. Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391. \n                      https:\/\/doi.org\/10.1002\/ana.25101.\n                      \n                     A longitudinal, prospective description of the natural history of type 1 spinal muscular atrophy.","journal-title":"Annals of Neurology"},{"issue":"1","key":"568_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell."},{"issue":"5","key":"568_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323.","journal-title":"Arch Neurol"},{"issue":"8","key":"568_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351. \n                      https:\/\/doi.org\/10.1177\/0883073807305673\n                      \n                    .","journal-title":"J Child Neurol"},{"issue":"12","key":"568_CR8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1212\/WNL.40.12.1831","volume":"40","author":"TL Munsat","year":"1990","unstructured":"Munsat TL, Skerry L, Korf B, Pober B, Schapira Y, Gascon GG, et al. Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q). Neurology. 1990;40(12):1831\u20136.","journal-title":"Neurology."},{"issue":"1","key":"568_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"Matthew D Mailman","year":"2002","unstructured":"Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4(1):20\u20136. \n                      https:\/\/doi.org\/10.1097\/00125817-200201000-00004\n                      \n                    .","journal-title":"Genetics in Medicine"},{"issue":"3","key":"568_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408\u201313. \n                      https:\/\/doi.org\/10.1016\/j.ajhg.2009.08.002\n                      \n                    .","journal-title":"Am J Hum Genet"},{"key":"568_CR11","unstructured":"CureSMA. New York to implement newborn screening for SMA October 1st. 2018."},{"issue":"2","key":"568_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145\u201358. \n                      https:\/\/doi.org\/10.3233\/JND-180304\n                      \n                    .","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"568_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979\u201384. \n                      https:\/\/doi.org\/10.1001\/archneurol.2011.74\n                      \n                    .","journal-title":"Arch Neurol"},{"issue":"3","key":"568_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207. \n                      https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004\n                      \n                    .","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"568_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. \n                      https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005\n                      \n                    .","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"568_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. \n                      https:\/\/doi.org\/10.1212\/WNL.0000000000000741\n                      \n                    .","journal-title":"Neurology"},{"issue":"10063","key":"568_CR17","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8\n                      \n                    .","journal-title":"Lancet."},{"issue":"18","key":"568_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"Richard S. Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1702752.\n                      \n                     Prospective, randomized, double-blind study showing the efficacy of nusinersen for the treatment of type 1 spinal muscular atrophy.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"568_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1710504\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"10","key":"568_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u20137. \n                      https:\/\/doi.org\/10.1212\/WNL.0000000000002445\n                      \n                    .","journal-title":"Neurology."},{"issue":"12","key":"568_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/pan.13500","volume":"28","author":"AR Bielsky","year":"2018","unstructured":"Bielsky AR, Fuhr PG, Parsons JA, Yaster M. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen. Paediatr Anaesth. 2018;28(12):1105\u20138. \n                      https:\/\/doi.org\/10.1111\/pan.13500\n                      \n                    .","journal-title":"Paediatr Anaesth"},{"key":"568_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10072-018-3622-9","volume":"40","author":"VA Sansone","year":"2018","unstructured":"Sansone VA, Albamonte E, Salmin F, Casiraghi J, Pirola A, Bettinelli M, et al. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. Neurol Sci. 2018;40:327\u201332. \n                      https:\/\/doi.org\/10.1007\/s10072-018-3622-9\n                      \n                    .","journal-title":"Neurol Sci"},{"key":"568_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","volume":"266","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Winter B, Wollinsky K, Ludolph AC, Uzelac Z, Witzel S, et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. J Neurol. 2018;266:183\u201394. \n                      https:\/\/doi.org\/10.1007\/s00415-018-9124-0\n                      \n                    .","journal-title":"J Neurol"},{"key":"568_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2014.00042","volume":"8","author":"DJ Schuster","year":"2014","unstructured":"Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014;8:42. \n                      https:\/\/doi.org\/10.3389\/fnana.2014.00042\n                      \n                    .","journal-title":"Front Neuroanat"},{"issue":"3","key":"568_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271\u20134. \n                      https:\/\/doi.org\/10.1038\/nbt.1610\n                      \n                    .","journal-title":"Nat Biotechnol"},{"issue":"3","key":"568_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","volume":"77","author":"SI Duque","year":"2015","unstructured":"Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. 2015;77(3):399\u2013414. \n                      https:\/\/doi.org\/10.1002\/ana.24332\n                      \n                    .","journal-title":"Ann Neurol"},{"issue":"3","key":"568_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23(3):477\u201387. \n                      https:\/\/doi.org\/10.1038\/mt.2014.210\n                      \n                    .","journal-title":"Mol Ther"},{"issue":"18","key":"568_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Jerry R. Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1706198.\n                      \n                     Prospective study showing the safety and efficacy of gene replacement therapy in type 1 spinal muscular atrophy.","journal-title":"New England Journal of Medicine"},{"key":"568_CR29","doi-asserted-by":"publisher","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2018. \n                      https:\/\/doi.org\/10.1002\/ppul.24203\n                      \n                    .","DOI":"10.1002\/ppul.24203"},{"issue":"11","key":"568_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/hum.2014.057","volume":"25","author":"E Ayuso","year":"2014","unstructured":"Ayuso E, Blouin V, Lock M, McGorray S, Leon X, Alvira MR, et al. Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther. 2014;25(11):977\u201387. \n                      https:\/\/doi.org\/10.1089\/hum.2014.057\n                      \n                    .","journal-title":"Hum Gene Ther"},{"issue":"6197","key":"568_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688\u201393. \n                      https:\/\/doi.org\/10.1126\/science.1250127\n                      \n                    .","journal-title":"Science."},{"issue":"1","key":"568_CR32","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","volume":"8","author":"M Sivaramakrishnan","year":"2017","unstructured":"Sivaramakrishnan M, McCarthy KD, Campagne S, Huber S, Meier S, Augustin A, et al. Binding to SMN2 pre- mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun. 2017;8(1):1476. \n                      https:\/\/doi.org\/10.1038\/s41467-017-01559-4\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"7","key":"568_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","volume":"11","author":"J Palacino","year":"2015","unstructured":"Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015;11(7):511\u20137. \n                      https:\/\/doi.org\/10.1038\/nchembio.1837\n                      \n                    .","journal-title":"Nat Chem Biol"},{"key":"568_CR34","unstructured":"F. Hoffman-La Roche P. Update on clinical development of RG7800. 2015."},{"key":"568_CR35","unstructured":"Novartis. Novartis Releases Update on LMI070 (Branaplam) Clinical Trial. 2017."},{"issue":"2","key":"568_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/ph3020345","volume":"3","author":"T Bordet","year":"2010","unstructured":"Bordet T, Berna P, Abitbol JL, Pruss RM. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel). 2010;3(2):345\u201368. \n                      https:\/\/doi.org\/10.3390\/ph3020345\n                      \n                    .","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"568_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo- controlled phase 2 trial. Lancet Neurol. 2017;16(7):513\u201322. \n                      https:\/\/doi.org\/10.1016\/S1474-4422(17)30085-6\n                      \n                    .","journal-title":"Lancet Neurol"},{"issue":"5","key":"568_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mus.26017","volume":"57","author":"JA Andrews","year":"2018","unstructured":"Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57(5):729\u201334. \n                      https:\/\/doi.org\/10.1002\/mus.26017\n                      \n                    .","journal-title":"Muscle Nerve"},{"issue":"7","key":"568_CR39","first-page":"2897","volume":"8","author":"Y Yu","year":"2016","unstructured":"Yu Y, Zhang P, Han N, Kou Y, Yin X, Jiang B. Collateral development and spinal motor reorganization after nerve injury and repair. Am J Transl Res. 2016;8(7):2897\u2013911.","journal-title":"Am J Transl Res"},{"issue":"4","key":"568_CR40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4103\/jnrp.jnrp_173_17","volume":"8","author":"MG Senol","year":"2017","unstructured":"Senol MG, Kaplan C, Ozdag F, Saracoglu M. How long does denervation take in poliomyelitis? Or is it a lifetime? J Neurosci Rural Pract. 2017;8(4):511\u20135. \n                      https:\/\/doi.org\/10.4103\/jnrp.jnrp_173_17\n                      \n                    .","journal-title":"J Neurosci Rural Pract"},{"issue":"2","key":"568_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","volume":"3","author":"SJ Kolb","year":"2016","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3(2):132\u201345. \n                      https:\/\/doi.org\/10.1002\/acn3.283\n                      \n                    .","journal-title":"Ann Clin Transl Neurol"},{"key":"568_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/B978-0-12-803685-3.00024-0","volume-title":"Spinal muscular atrophy: disease mechanisms and therapy","author":"WD Arnold","year":"2017","unstructured":"Arnold WD, Rutkove S, Simard L, Kolb SJ. Development and testing of biomarkers in spinal muscular atrophy. In: Sumner CJ, Paushkin S, Ping C-P, editors. Spinal muscular atrophy: disease mechanisms and therapy. San Diego: Academic Press; 2017. p. 383\u201397."},{"issue":"3","key":"568_CR43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00415-017-8730-6","volume":"265","author":"Daniela Rossi","year":"2018","unstructured":"Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265(3):510\u201321. \n                      https:\/\/doi.org\/10.1007\/s00415-017-8730-6\n                      \n                    .","journal-title":"Journal of Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-019-0568-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:29:00Z","timestamp":1588030140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-019-0568-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s11940-019-0568-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"29 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Stephen J. Kolb reports consulting fees from AveXis, Biogen Idec, and Genentech outside the submitted work. Megan A. Waldrop reports personal fees from The France Foundation outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"25"}}